HZHilal Zıvalı

Hilal Zıvalı

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hilal Zıvalı has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    From Fragments to Function: Novel Hydrazone Derivatives as Monoamine Oxidase Inhibitors

    by Hasan Erdinç Sellitepe, Ahmet Buğra Aksel, Ezgi Pehlivanlar Yavrucu, Hilal Zıvalı, Begüm Nurpelin Sağlık Özkan, İnci Selin Doğan

    Monoamine oxidase (MAO) catalyzes the breakdown of neurotransmitters, including serotonin, dopamine, and norepinephrine. There are two isoforms of this enzyme: MAO‐A and MAO‐B. MAO efficacy is widely investigated in neurodegenerative (MAO‐B) and depressive (MAO‐A) disorders. Upon examining the structures of known inhibitors, it becomes evident that many share an aliphatic amine structure. Furthermore, the literature suggests that compounds with naphthalene skeletons, phenolic structures, and hydrazone moieties exhibit MAO inhibitory activity. In this study, 12 N ‐acylhydrazone derivatives ( 5a–f , 6a–f ) were designed using ligand‐based design methods. Based on biological activity studies, the MAO‐A inhibition of the compounds was calculated to be 0.073–2.54 µM, and the MAO‐B inhibition was 0.064–3.147 µM. Among all compounds, the derivatives bearing a naphthalene ring ( 5d – f , 6d – f ) exhibited MAO enzyme inhibition at levels comparable to those of the reference compounds. The compound with the highest activity, 6e , had IC 50 values of 0.073 ± 0.002 and 0.064 ± 0.002 µM against MAO‐A and MAO‐B, respectively. Due to its superior potency against human MAO‐B, enzyme kinetic studies were further conducted on compound 6e . Consequently, the pronounced inhibitory potency, reversible competitive kinetics, and favorable pharmacokinetic profile of compound 6e designate it as a strong lead candidate for advanced preclinical evaluation.


  • Structure‐Guided Optimization of 1,2,4‐Triazole‐Thione‐Based Mannich Derivatives as Dual‐Target Modulators: AChE / MAO ‐B

    by Hasan Erdinç Sellitepe, Ahmet Buğra Aksel, Hilal Zıvalı, Ezgi Pehlivanlar Yavrucu, Begüm Nurpelin Sağlık Özkan, İnci Selin Doğan, Kutsal Özcan Kosif

    Diseases such as Alzheimer's, Parkinson's, and depression result from neurotransmitter imbalances. In particular, for AD, it is critical to inhibit AChE to preserve the decline in acetylcholine levels and to block excessive MAO‐B activity, which leads to nerve damage and cognitive impairment. As current scientific research has moved away from the “one drug for one target” approach toward a “multi‐target” strategy, dual‐acting inhibitors that simultaneously inhibit both AChE and MAO‐B enzymes are considered the most promising new drug candidates for the treatment of Alzheimer's disease. In this study, we investigated the inhibition of AChE, BChE, MAO‐A, and MAO‐B in the pathophysiology of AD as a working group. Within the scope, 10 new compounds ( 5a – j ) were synthesized, consisting of a phenolic ring, a secondary or tertiary amine tail, and a 1,2,4‐triazole core. The cholinesterase and MAO inhibitory profiles of the compounds were investigated using both in vitro and in silico methods. Compound 5b exhibited dual inhibitory activity against AChE and MAO‐B enzymes, with IC 50 values of 0.136 ± 0.006 μM and 0.108 ± 0.005 μM, respectively. In accordance with 5b , it interacted with crucial amino acids of the h AChE and h MAO‐B enzymes in the docking studies. These results suggest that 5b is a dual‐target inhibitor of AChE and MAO‐B and represents a promising therapeutic option for the treatment of Alzheimer's disease.